AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12356658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 10077777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.i.d. for 10 days)
Number of subjects: 501
Study 10077777 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg b.i.d. for 10 days)
Number of subjects: 501
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 5 mg atipamezole hydrochloride
Number of subjects: 15
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 10 mg atipamezole hydrochloride
Number of subjects: 15
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 20 mg atipamezole hydrochloride
Number of subjects: 15
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal administration of 40 mg atipamezole hydrochloride
Number of subjects: 15
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg atipamezole hydrochloride
Number of subjects: 15
Study 7586944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg atipamezole hydrochloride
Number of subjects: 15
Study 2181789 — intervention group
Group type: EXPERIMENTAL
Intervention: YAL-irrigation
Number of subjects: 60
Study 2181789 — intervention group
Group type: COMPARATOR
Intervention: PEG (polyethylene glycol electrolyte)
Number of subjects: 60
Study 36449 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 14
Study 36449 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning with abdomen protruding freely
Number of subjects: 14
Study 36449 — intervention group
Group type: COMPARATOR
Intervention: Prone positioning with abdomen restricted
Number of subjects: 14
Study 31838561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-VRL (60 mg/m2 for cycle 1, 80 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Number of subjects: 133
Study 31838561 — intervention group
Group type: COMPARATOR
Intervention: IV-VRL (25 mg/m2 for cycle 1, 30 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Number of subjects: 133
Study 28736942 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0
Study 28736942 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study 27044546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin at 1 g daily for three consecutive days
Number of subjects: 200
Study 27044546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25540273 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/HPV-18 AS04-adjuvanted vaccine
Number of subjects: 0
Study 25540273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 0
Study 23788532 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 255
Study 20529982 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 100
Study 20529982 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100
Study 18927461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 6483
Study 18927461 — intervention group
Group type: COMPARATOR
Intervention: Pooled RCTs
Number of subjects: 6483
Study 16600938 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density complementary foods (1.5 kcal/g)
Number of subjects: 10
Study 16600938 — intervention group
Group type: COMPARATOR
Intervention: Low energy density complementary foods (0.4 kcal/g)
Number of subjects: 10
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dried dentin rewet with Protect
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dry dentin
Number of subjects: 180
Study 12760701 — intervention group
Group type: COMPARATOR
Intervention: Syntac Single‐Component with Heliomolar resin composite to moist dentin (control)
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dried dentin rewet with Protect
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dry dentin
Number of subjects: 180
Study 12760701 — intervention group
Group type: COMPARATOR
Intervention: OptiBond Solo Plus with Point 4 resin composite to moist dentin (control)
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dried dentin rewet with Protect
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dry dentin
Number of subjects: 180
Study 12760701 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond NT with TPH Spectrum resin composite to moist dentin (control)
Number of subjects: 180
Study 12760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180
Study 10807483 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated RUL ECT at 2.25 times initial seizure threshold (mean dose, 136 mC)
Number of subjects: 72
Study 10807483 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose RUL ECT at 403 mC
Number of subjects: 72
Study 9264420 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg/day)
Number of subjects: 6605
Study 9264420 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6605
Study 8099492 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 1‐adrenergic blocker doxazosin (2 mg/day)
Number of subjects: 16
Study 8099492 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 2893448 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.5 CU/kg/h)
Number of subjects: 9
Study 2893448 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 micrograms/kg/h)
Number of subjects: 9
Study 2893448 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 9
Study 2893448 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 9
Study 2893448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31702415 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, tailored intervention (Puff City)
Number of subjects: 0
Study 31702415 — intervention group
Group type: COMPARATOR
Intervention: Generic web-based asthma education (control)
Number of subjects: 0
Study 28758531 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 150
Study 28758531 — intervention group
Group type: COMPARATOR
Intervention: Delayed amniotomy
Number of subjects: 150
Study 27563680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month, 6-session diabetes-related social support groups (SSG)
Number of subjects: 47
Study 27563680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 27563680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month diabetes self-management education intervention (DSME)
Number of subjects: 47
Study 24531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (N-BES)
Number of subjects: 120
Study 24531309 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 120
Study 22614285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) 800 mg and chondroitin sulfate (CS) 1 g in 50 mL of saline solution once weekly for 4 weeks then once every 2 weeks twice more (group 1)
Number of subjects: 28
Study 22614285 — intervention group
Group type: COMPARATOR
Intervention: Long term antibiotic prophylaxis using sulfamethoxazole 200 mg and trimethoprim 40 mg once weekly for 6 weeks (group 2; control)
Number of subjects: 28
Study 20153690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (D2)
Number of subjects: 15
Study 20153690 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (B2)
Number of subjects: 15
Study 20153690 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (C2)
Number of subjects: 15
Study 20153690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (A2)
Number of subjects: 15
Study 18713150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse, 0.2% CHX digluconate, three times a day for 7 days before TTBPE removal
Number of subjects: 51
Study 18713150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antimicrobial treatment)
Number of subjects: 51
Study 18713150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse
Number of subjects: 51
Study 16463767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dix-Hallpike maneuver
Number of subjects: 72
Study 16463767 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying maneuver
Number of subjects: 72
Study 16463767 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll test
Number of subjects: 72
Study 11752105 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.01-1.0 mg/kg)
Number of subjects: 25
Study 11752105 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.2-0.4 mg/kg)
Number of subjects: 25
Study 11752105 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (1.0 mg/kg)
Number of subjects: 25
Study 11752105 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study 9676891 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg/kg dynorphin A (1-13)
Number of subjects: 4
Study 9676891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg/kg dynorphin A (1-13)
Number of subjects: 4
Study 9676891 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg/kg dynorphin A (1-13)
Number of subjects: 4
Study 9676891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 8004311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 10
Study 2512372 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-chest position
Number of subjects: 15
Study 2512372 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Control)
Number of subjects: 15
Study 804397 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral carbohydrates combined with essential amino acids and histidine
Number of subjects: 24
Study 804397 — intervention group
Group type: COMPARATOR
Intervention: Water and electrolyte balance
Number of subjects: 24
Study 804397 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 24
Study 6782862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine b.i.d.
Number of subjects: 11
Study 6782862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31610033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 47
Study 31610033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 47
Study 31610033 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47
Study 29037630 — intervention group
Group type: EXPERIMENTAL
Intervention: High velocity low amplitude technique (HVLA)
Number of subjects: 75
Study 29037630 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 75
Study 29037630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Lateral glide mobilization (CLGM)
Number of subjects: 75
Study 25732915 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system (PMI)
Number of subjects: 38
Study 25732915 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA surgical instrumentation (STD)
Number of subjects: 38
Study 23398227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum treatment
Number of subjects: 194
Study 23398227 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 194
Study 21491990 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chips
Number of subjects: 24
Study 21491990 — intervention group
Group type: COMPARATOR
Intervention: Placebo chips
Number of subjects: 24
Study 19722727 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute frequency format
Number of subjects: 187
Study 19722727 — intervention group
Group type: COMPARATOR
Intervention: Verbal format
Number of subjects: 187
Study 19722727 — intervention group
Group type: COMPARATOR
Intervention: Combined format
Number of subjects: 187
Study 17188609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 711
Study 17188609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT)
Number of subjects: 711
Study 17188609 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT) and low FPIR
Number of subjects: 711
Study 17188609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors (BMI, FPIR, 2-hour glucose)
Number of subjects: 711
Study 14767260 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 4 kcal/kg/week)
Number of subjects: 450
Study 14767260 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 8 kcal/kg/week)
Number of subjects: 450
Study 14767260 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 12 kcal/kg/week)
Number of subjects: 450
Study 14767260 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 450
Study 12023757 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) implant
Number of subjects: 200
Study 12023757 — intervention group
Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 200
Study 9855418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines
Number of subjects: 2497
Study 9855418 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2497
Study 8011010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg every 6 h)
Number of subjects: 100
Study 8011010 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg every 8 h)
Number of subjects: 100
Study 2492166 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone‐releasing factor (GH‐RF) (1 microgram/kg i.v.)
Number of subjects: 22
Study 2492166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1096540 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg per day of temazepam
Number of subjects: 20
Study 1096540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31055542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama breathing exercises for 15 minutes daily for 1 month
Number of subjects: 70
Study 31055542 — intervention group
Group type: COMPARATOR
Intervention: MyCalmBeat portable device
Number of subjects: 70
Study 27682437 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday sunlight exposure
Number of subjects: 1312
Study 27682437 — intervention group
Group type: COMPARATOR
Intervention: Dietary vitamin D intake
Number of subjects: 1312
Study 25331972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirksen stomach tube
Number of subjects: 5
Study 25331972 — intervention group
Group type: EXPERIMENTAL
Intervention: Geishauser stomach tube
Number of subjects: 5
Study 25331972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube 4
Number of subjects: 5
Study 25331972 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple water hose used with a gag
Number of subjects: 5
Study 25331972 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study 23834229 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% w/v chlorhexidine varnish coating
Number of subjects: 983
Study 23834229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 983
Study 21670470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR)
Number of subjects: 80
Study 21670470 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide, and rituximab (as salvage therapy)
Number of subjects: 80
Study 19751458 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 301
Study 19751458 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 301
Study 19751458 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 301
Study 19751458 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 301
Study 18198776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tenoxicam 20 mg
Number of subjects: 30
Study 18198776 — intervention group
Group type: COMPARATOR
Intervention: Oral tenoxicam 20 mg a day for 10 days
Number of subjects: 30
Study 15051552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1.05 g daily for 3 weeks)
Number of subjects: 291
Study 15051552 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 (75 mg daily for 3 weeks)
Number of subjects: 291
Study 11996757 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in clinical trials (CT) for essential hypertension
Number of subjects: 73
Study 9690699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (a selective androgen receptor antagonist)
Number of subjects: 13
Study 7516637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4
Number of subjects: 20
Study 7516637 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4 with added alpha interferon (IFN-alpha) 3 MU s.c., three times weekly from days 1 to 21
Number of subjects: 20
Study 7516637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) and 5-fluorouracil (5-FU) with recombinant granulocyte colony stimulating factor (G-CSF) 5 micrograms/kg b.w. s.c. from days 7 to 18
Number of subjects: 20
Study 7516637 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (DDP), 5-fluorouracil (5-FU), and alpha interferon (IFN-alpha)
Number of subjects: 20
Study 2815647 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimetric waves treatment
Number of subjects: 50
Study 2815647 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 791351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Partusisten) aerosol, 5 puffs of 200 mug each
Number of subjects: 5
Study 791351 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 5
Study 31888702 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzhong Yiqi decoction plus standard therapy
Number of subjects: 200
Study 31888702 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study 28432842 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 136
Study 28432842 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolinic acid (QUIN)
Number of subjects: 136
Study 28432842 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenine
Number of subjects: 136
Study 28432842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 136
Study 25963758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate with single dose of calcium gluconate (SBCG1)
Number of subjects: 74
Study 25963758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate with double dose of calcium gluconate (SBCG2)
Number of subjects: 74
Study 22875194 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDFOOT
Number of subjects: 9
Study 22875194 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBI
Number of subjects: 9
Study 22875194 — intervention group
Group type: COMPARATOR
Intervention: NORM
Number of subjects: 9
Study 22875194 — intervention group
Group type: EXPERIMENTAL
Intervention: RACE
Number of subjects: 9
Study 22875194 — intervention group
Group type: EXPERIMENTAL
Intervention: FREQ
Number of subjects: 9
Study 21353124 — intervention group
Group type: EXPERIMENTAL
Intervention: Family practice-based depression case management
Number of subjects: 626
Study 21353124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 18565520 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine foot reflexology
Number of subjects: 48
Study 18565520 — intervention group
Group type: COMPARATOR
Intervention: Sham reflexology
Number of subjects: 48
Study 16642484 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at IMIP (Recife, Brazil)
Number of subjects: 433
Study 16642484 — intervention group
Group type: COMPARATOR
Intervention: Treatment at US centers
Number of subjects: 433
Study 14731162 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (ritonavir or indinavir)
Number of subjects: 1251
Study 14731162 — intervention group
Group type: COMPARATOR
Intervention: HAART regimen
Number of subjects: 1251
Study 14731162 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and zalcitabine in the prescribed regimen
Number of subjects: 1251
Study 11348957 — intervention group
Group type: EXPERIMENTAL
Intervention: IV theophylline
Number of subjects: 47
Study 11348957 — intervention group
Group type: COMPARATOR
Intervention: Control (no theophylline)
Number of subjects: 47
Study 9292946 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 62
Study 9292946 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 62